.Attribute Medicine, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- drug conjugate (ADC) tisotumab vedotin resulted in enhanced progression-free as well as total survival, leading to FDA approval and also a brand new treatment option for clients.